TICKERNERD
Menu
SNOASNOAHealthcare · Drug Manufacturers - Specialty & Generic

SNOA Stock Forecast: Sonoma Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.10
−8.33% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$5.7M
Ticker Nerd rank
35/ 100
Median analyst target
—
Analysts covering
0
Revenue$6.4M+59.6% y/y
Operating income−$40K
Net income−$330K
Free cash flow−$651K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.9%
1M
−14.1%
YTD
−69.8%
1Y
−72.2%
From 52W high
−72.2%
From 52W low
+8.9%
$1.01
$3.95
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SNOA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sonoma Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
35/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Growth
92
Quality
69
Value
47
Revisions
25
Accruals
23
Volatility
22
Momentum
18
Issuance
17

Size (94): Smaller than most of the companies we track.

Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SNOA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNOA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26SNOA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Sept 2023Ladenburg ThalmannInitiatesBuy$3.25
25 Nov 2020BenchmarkInitiatesSpeculative Buy—
25 Nov 2020Maxim GroupDowngradeHold—
6 Mar 2018Maxim GroupDowngradeHold—
28 Dec 2017BenchmarkInitiatesSpeculative Buy—
10 Nov 2017Maxim GroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SNOA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SNOA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Sonoma Pharmaceuticals, Inc. returned −72.2% against +12.4% for the S&P 500, dividends included.

SNOA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26SNOAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SNOA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Sonoma Pharmaceuticals, Inc. (SNOA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
0.3×

Cheaper than 89% of US stocks

Price / book
0.8×

Cheaper than 74% of US stocks

EV / EBITDA
−0.9×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
59.6%

Higher than 88% of US stocks

Earnings growth (YoY)
59.6%

Higher than 77% of US stocks

Gross margin
40.2%

Higher than 50% of US stocks

Operating margin
−0.6%

Higher than 31% of US stocks

Net margin
−10.3%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−42.5%

Higher than 24% of US stocks

Return on assets
−5.4%

Higher than 32% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sonoma Pharmaceuticals, Inc. (SNOA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sonoma Pharmaceuticals, Inc. has a market value of $5.7M and an enterprise value of $1.1M.

  • Revenue in the twelve months to 30 June 2026: $21.9M. The latest quarter grew 59.6% year on year.

  • Net income over the same four quarters: −$2.3M, a −10.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$2.7M.

  • Shares outstanding: 4.8M.

  • Trailing P/E: −0.6×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Sonoma Pharmaceuticals, Inc. employs 10 people — $2.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

SNOA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SNOASonoma Pharmaceuticals, Inc.$5.7M35
GELSGelteq Ltd.$5.2M11
APUSApimeds Pharmaceuticals US, Inc.$4.5M10
YCBDcbdMD, Inc.$4.3M26
UPCUniverse Pharmaceuticals, Inc.$7.5M28
INMInMed Pharmaceuticals, Inc.$8.8M41
AKANAkanda Corp.$2.7M10

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sonoma Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SNOA news & analysis

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Accesswire · 6 Aug 2026positive

Sonoma Pharmaceuticals reported fiscal Q1 2026 results with total revenue up 60% year over year to $6.4 million, U.S. revenue growth of 141%, and its first-ever positive adjusted EBITDA. Net loss per share fell 88% year over year, and gross margin expanded to 40%, supported by FDA clearance and new global distributors.

Why it matters — The company reached an inflection point with accelerating U.S. revenue, strong margin improvement, and its first positive adjusted EBITDA, marking a significant financial milestone for SNOA.

Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue

Benzinga · 6 Aug 2026positive

Sonoma Pharmaceuticals reported a first-quarter loss of 9 cents per share, significantly improved from a loss of 76 cents a year ago. The company also turned EBITDA positive for the first time, with record quarterly revenue.

Why it matters — A first-time EBITDA-positive quarter alongside record revenue and a sharply narrowed loss marks a notable improvement in the company's financial trajectory.

FAQ

Frequently asked questions about SNOA stock

How does Ticker Nerd's model rank SNOA?

As at 31 Oct 2026, Sonoma Pharmaceuticals, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the SNOA stock forecast for 2030?

No analyst covering Sonoma Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNOA are extrapolating price history, which says nothing about the business.

How has SNOA stock performed over the past year?

Sonoma Pharmaceuticals, Inc. returned -72.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sonoma Pharmaceuticals, Inc. do?

Sonoma Pharmaceuticals Inc. is a healthcare company that develops and manufactures stabilized hypochlorous acid (HOCl) products used across wound care, eye care, oral and nasal care, dermatology, podiatry, animal health, and non-toxic disinfection.

What is the latest news on SNOA?

The most recent item we track (Accesswire, 6 Aug 2026): "Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA". Sonoma Pharmaceuticals reported fiscal Q1 2026 results with total revenue up 60% year over year to $6.4 million, U.S. revenue growth of 141%, and its first-ever positive adjusted EBITDA. Net loss per share fell 88% year over year, and gross margin expanded to 40%, supported by FDA clearance and new global distributors.

Company

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Inc. is a healthcare company that develops and manufactures stabilized hypochlorous acid (HOCl) products used across wound care, eye care, oral and nasal care, dermatology, podiatry, animal health, and non-toxic disinfection. Its portfolio is built around topical and cleansing solutions designed for sensitive skin and tissue, supporting clinicians and patients in managing irritation, infection risk, and recovery in both medical and consumer settings. Sonoma Pharmaceuticals markets its products internationally through healthcare and specialty channels, with applications spanning acute and chronic care environments as well as veterinary uses. The company also focuses on advanced tissue care and other topical formulations, making it a niche participant in the broader pharmaceutical and medical products market. Sonoma Pharmaceuticals Inc. is headquartered in Boulder, Colorado.

CEO Ms. Amy M. Trombly Esq., J.D. · 10 employees · United States · https://sonomapharma.com